Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma

Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma

Abstract Background Circulating tumor (ct) DNA assays performed in clinical laboratories provide tumor biomarker testing support for biopharmaceutical clinical trials. Yet it is neither practical nor economically feasible for many of these clinical laboratories to internally develop their own liquid...

Full description

Bibliographic Details
Main Authors: Suman Verma, Mathew W. Moore, Rebecca Ringler, Abhisek Ghosal, Kyle Horvath, Theodore Naef, Sheri Anvari, Philip D. Cotter, Shelly Gunn
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Cancer
Subjects:
ctDNA
Liquid biopsy
Tumor biomarkers
NGS
Online Access:http://link.springer.com/article/10.1186/s12885-020-07445-5

Internet

http://link.springer.com/article/10.1186/s12885-020-07445-5

Similar Items